08:00 , Dec 8, 2014 |  BC Week In Review  |  Financial News

Pieris completes venture financing

Pieris AG , Freising-Weihenstephan, Germany   Business: Cancer, Inflammation, Ophthalmic   Date completed: 2014-11-26   Type: Venture financing   Raised: €6.6 million ($8.2 million)   Investors: Ally Bridge Group; OrbiMed Advisors; Global Life Science Ventures;...
07:00 , Jul 28, 2014 |  BioCentury  |  Emerging Company Profile

amcure: Reimagining angiogenesis

amcure GmbH is developing peptide-based inhibitors of CD44v6 , a tumor-specific co-receptor of tyrosine kinases including VEGFR-2 and c-Met . The approach could allow for higher dosing with fewer side effects than direct-acting tyrosine kinase...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Financial News

amcure completes venture financing

amcure GmbH , Eggenstein-Leopoldshafen, Germany   Business: Cancer   Date completed: 2014-07-15   Type: Venture financing   Raised: EUR5 million ($6.8 million)   Investors: LBBW Venture Capital; KfW; MBG Baden-Wuerttemberg; S-Kap Beteiligungen Pforzheim; BioM; private...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Financial News

conoGenetix completes venture financing

conoGenetix biosciences GmbH , Martinsried, Germany   Business: Autoimmune   Date completed: 4/18/12   Type: Venture financing   Raised: More than €1.5 million ($2 million)   Investors: Mey Capital Matrix; BioM   Note: The company...
00:31 , Apr 24, 2012 |  BC Extra  |  Financial News

conoGenetix raises EUR 1.5 million in Series A

conoGenetix biosciences GmbH (Martinsried, Germany) raised more than EUR 1.5 million ($2 million) in a series A round led by Mey Capital Matrix. BioM also participated. conoGenetix has a pipeline of preclinical peptides that antagonize...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Financial News

Kinaxo completes venture financing

Kinaxo Biotechnologies GmbH , Martinsried, Germany   Business: Proteomics, Supply/Service   Date completed: 11/20/09   Type: Venture financing   Raised: Undisclosed   Investors: Leifina; Conmit Invest; Mountain Partners; BioM; High-Tech-Grunderfonds; Max Planck Society; KfW; private...
07:00 , Oct 29, 2007 |  BC Week In Review  |  Clinical News

PX-866: Phase I start

Early next year, BIOM hopes to begin a Phase I trial. Biomira Inc. (TSX:BRA; BIOM), Edmonton, Alberta   Product: PX-866   Business: Cancer   Molecular target: Not available   Description: Inhibitor of the PI-3-kinase/ PTEN...
07:00 , Sep 10, 2007 |  BC Week In Review  |  Clinical News

Stimuvax: Updated Phase IIb data

Updated data from an open-label Phase IIb trial showed that 49% of patients with Stage IIIb locoregional disease who received Stimuvax plus standard care were alive after 3 years vs. 27% of patients receiving standard...
07:00 , Sep 3, 2007 |  BC Week In Review  |  Clinical News

PX-478: Phase I started

BRA began an open-label, dose-escalation, U.S. Phase I trial in 36 patients who failed or are intolerant with standard therapy to evaluate oral PX-478 given on days 1-5 during a 21-day cycle. Biomira Inc. (TSX:BRA;...
07:00 , Aug 13, 2007 |  BC Week In Review  |  Company News

Biomira, Merck KGaA deal

The partners added Canada to MRK's license covering BRA's Stimuvax cancer vaccine. MRK now has worldwide rights to develop and market the liposomal vaccine containing a synthetic, 25-amino acid peptide sequence from MUC-1 ( CD227...